The	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	B:C0728747
for	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
:	O
a	O
meta-	O
analysis	I:C0920317
of	O
five	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

The	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
for	O
advanced	B:C0024623
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
:	O
a	O
meta-	O
analysis	I:C0920317
of	O
five	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

The	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
for	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	B:C1112160
cancer	I:C1112160
:	O
a	O
meta-	O
analysis	I:C0920317
of	O
five	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

The	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
for	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
:	O
a	O
meta-	B:C0920317
analysis	I:C0920317
of	O
five	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
.	O

The	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
for	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
:	O
a	O
meta-	O
analysis	I:C0920317
of	O
five	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
.	O

A	O
meta-analysis	B:C0920317
was	O
performed	O
to	O
examine	O
the	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
in	O
patients	O
with	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
(	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
)	O
.	O

A	O
meta-analysis	O
was	O
performed	O
to	O
examine	O
the	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	B:C0728747
in	O
patients	O
with	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
(	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
)	O
.	O

A	O
meta-analysis	O
was	O
performed	O
to	O
examine	O
the	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
in	O
patients	O
with	O
advanced	B:C0024623
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
(	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
)	O
.	O

A	O
meta-analysis	O
was	O
performed	O
to	O
examine	O
the	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
in	O
patients	O
with	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	B:C1112160
cancer	I:C1112160
(	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
)	O
.	O

A	O
meta-analysis	O
was	O
performed	O
to	O
examine	O
the	O
efficiency	O
and	O
safety	O
of	O
trastuzumab	O
in	O
patients	O
with	O
advanced	O
gastric	I:C0024623
and	O
gastroesophageal	O
cancer	I:C1112160
(	O
and	B:C1112160
gastroesophageal	I:C1112160
cancer	I:C1112160
)	O
.	O

By	O
searching	O
multiple	O
databases	B:C0242356
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	B:C0728747
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	B:C0003393
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	B:C0003393
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	B:C3665472
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	B:C3665472
alone	I:C3665472
)	O
in	O
gastric	O
cancer	I:C0024623
would	O
be	O
included	O
.	O

By	O
searching	O
multiple	O
databases	O
from	O
1990	O
to	O
March	O
2016	O
,	O
all	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
(	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
)	O
which	O
compared	O
the	O
effect	O
of	O
trastuzumab	O
-	O
combined	O
chemotherapy	I:C0003393
(	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
)	O
versus	O
chemotherapy	O
alone	O
(	O
chemotherapy	O
alone	I:C3665472
)	O
in	O
gastric	B:C0024623
cancer	I:C0024623
would	O
be	O
included	O
.	O

Five	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
with	O
a	O
total	O
of	O
875	O
patients	O
were	O
included	O
.	O

Trastuzumab	B:C0728747
can	O
improve	O
the	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
one	O
-	O
year	O
survival	O
rate	O
,	O
two	O
-	O
year	O
survival	O
rate	O
and	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
of	O
patients	O
with	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
.	O

Trastuzumab	O
can	O
improve	O
the	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
one	O
-	O
year	O
survival	O
rate	O
,	O
two	O
-	O
year	O
survival	O
rate	O
and	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
of	O
patients	O
with	O
and	B:C1112160
gastroesophageal	I:C1112160
cancer	I:C1112160
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	B:C0450094
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	B:C0547054
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	B:C0879626
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	B:C0042963
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	B:C0027497
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	B:C0027947
,	O
thrombocytopaenia	O
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	B:C0040034
and	O
anemia	O
.	O

There	O
were	O
no	O
difference	O
between	O
the	O
two	O
arms	O
in	O
terms	O
of	O
grade	O
3	I:C0450094
/	O
4	O
adverse	O
effects	I:C0879626
,	O
such	O
as	O
vomiting	O
,	O
nausea	O
,	O
neutropenia	O
,	O
thrombocytopaenia	O
and	O
anemia	B:C0002871
.	O

Diarrhea	B:C0011991
increased	O
in	O
trastuzumab	O
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
group	O
.	O

Diarrhea	O
increased	O
in	O
trastuzumab	B:C0003393
-	I:C0003393
combined	I:C0003393
chemotherapy	I:C0003393
group	O
.	O

Trastuzumab	B:C0728747
can	O
significantly	O
improve	O
the	O
survival	O
rate	O
,	O
PFS	O
,	O
ORR	O
of	O
patients	O
with	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
.	O

Trastuzumab	O
can	O
significantly	O
improve	B:C0184511
the	O
survival	O
rate	O
,	O
PFS	O
,	O
ORR	O
of	O
patients	O
with	O
and	O
gastroesophageal	I:C1112160
cancer	I:C1112160
.	O

Trastuzumab	O
can	O
significantly	O
improve	O
the	O
survival	O
rate	O
,	O
PFS	O
,	O
ORR	O
of	O
patients	O
with	O
and	B:C1112160
gastroesophageal	I:C1112160
cancer	I:C1112160
.	O

It	O
is	O
safe	O
and	O
feasible	O
and	O
can	O
be	O
tolerated	B:C0243095
.	O

It	O
needs	O
further	O
prospective	O
multinational	O
multicenter	B:C0206012
randomized	O
controlled	I:C0206035
trials	I:C0206035
with	O
large	O
samples	O
to	O
define	O
the	O
clinical	O
benefits	O
of	O
trastuzumab	O
.	O

It	O
needs	O
further	O
prospective	O
multinational	O
multicenter	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
with	O
large	O
samples	O
to	O
define	O
the	O
clinical	O
benefits	O
of	O
trastuzumab	O
.	O

It	O
needs	O
further	O
prospective	O
multinational	O
multicenter	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
with	O
large	O
samples	O
to	O
define	O
the	O
clinical	O
benefits	O
of	O
trastuzumab	B:C0728747
.	O

